FGFR2 overexpression
|
Gastric Cancer
|
FGFR2 overexpression
|
Gastric Cancer
|
AMG 552 Sensitive: C2 – Inclusion Criteria
|
AMG 552 Sensitive: C2 – Inclusion Criteria
|
FGFR2 overexpression
|
Lung Non-Small Cell Squamous Cancer
|
FGFR2 overexpression
|
Lung Non-Small Cell Squamous Cancer
|
BAY 1163877 Resistant: C3 – Early Trials
|
BAY 1163877 Resistant: C3 – Early Trials
|
FGFR2 overexpression
|
Gastrointestinal Cancer
|
FGFR2 overexpression
|
Gastrointestinal Cancer
|
ARQ 087 Sensitive: D – Preclinical
|
ARQ 087 Sensitive: D – Preclinical
|
FGFR2 overexpression
|
Breast Cancer
|
FGFR2 overexpression
|
Breast Cancer
|
ponatinib Sensitive: D – Preclinical
|
ponatinib Sensitive: D – Preclinical
|
FGFR2 overexpression
|
Breast Cancer
|
FGFR2 overexpression
|
Breast Cancer
|
FGFR inhibitor Sensitive: D – Preclinical
|
FGFR inhibitor Sensitive: D – Preclinical
|